# Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

> **NCT00034281** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 16 (actual)

## Conditions studied

- Breast Neoplasm
- Pancreatic Neoplasm
- Lung Neoplasm
- Ovarian Neoplasm
- Renal Neoplasm

## Interventions

- **DRUG:** TAK-165

## Key facts

- **NCT ID:** NCT00034281
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2012-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034281, "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00034281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*